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of high cholesterol levels differ in how they are metabolized, 
their effects on other serum lipid components, bioavailabil-
ity, and potency.6-10 The 2 most commonly prescribed statins 
in the United States are atorvastatin and simvastatin, with 
simvastatin being available as a lower-cost generic drug 
since mid-2006. Compared with simvastatin, atorvastatin 
results in a greater reduction in low-density lipoprotein cho-
lesterol levels per milligram across all doses.11
 In the only head-to-head clinical outcomes trial of ator-
vastatin vs simvastatin in patients with established CHD, 
high-dose atorvastatin and usual-dose simvastatin did not 
differ significantly in the primary end 
point of major coronary events, but 
high-dose atorvastatin was associated 
with a statistically significant reduc-
tion in several secondary end points 
relative to usual-dose simvastatin 
(nonfatal acute myocardial infarction, major cardiovas-
cular events, and any coronary event).12 In observational 
studies of large US administrative insurance claims data-
bases, atorvastatin treatment has been associated with a 
lower risk of cardiovascular-related hospital admissions 
compared with simvastatin treatment among all patients 
in whom statin therapy was initiated13 and among patients 
free of cardiovascular disease in whom statin therapy was 
initiated for primary prevention.14,15 Similarly, in analyses 
of a general practice research database in the Netherlands, 
new statin users who were prescribed atorvastatin expe-
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Coronary heart disease (CHD) affects 13.2 million adults in the United States, resulting in total costs to 
society of $142.5 billion annually.1 Indirect costs attributed 
to CHD due to lost productivity, medically related absen-
teeism, or mortality account for almost half of this total, 
with CHD affecting substantial fractions of working-age 
adults.1 A population of almost 100 million adults in the 
United States1 is affected by high cholesterol levels (≥240 
mg/dL; to convert to mmol/L, multiply by 0.0259), a major 
risk factor for CHD. More than half the costs attributed to 
high cholesterol levels are due to lost productivity.2
 The primary treatments for lowering cholesterol levels, 
3-hydroxy-3-methylglutaryl coenzyme A reductase in-
hibitors or statins, reduce the risk of CHD,3,4 reduce direct 
medical costs and indirect costs, and may even lead to net 
cost savings.5 The many statins indicated for the treatment 
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OBJECTIVE: To compare the risk of cardiovascular-related hospi-
talization, statin adherence, and direct (medical and drug) and 
indirect (disability and medically related absenteeism) costs in 
US employees in whom atorvastatin or simvastatin was newly 
prescribed. 
PATIENTS AND METHODS: Active employees aged 18 to 64 years 
with a new atorvastatin or simvastatin prescription were identi-
fied from a deidentified claims database for 23 privately insured 
US companies from January 1, 1999, through December 31, 2006. 
Employees given atorvastatin were matched to those given sim-
vastatin according to propensity scores based on patient charac-
teristics, index statin dose, preindex cardiovascular events, and 
wage. Outcomes were compared between matched cohorts during 
the 2-year postindex period, including the risk of cardiovascular-
related hospitalization, adherence to the index statin, use of other 
lipid-lowering drugs, direct medical costs for third-party payers, 
and indirect costs to employers. Indirect costs were computed 
as follows: Disability Payments + Daily Wage × Days of Medically 
Related Absenteeism. Atorvastatin and simvastatin drug costs 
were imputed using recent pricing to account for the availability 
of lower-cost generic simvastatin after the study period.
RESULTS: Among 13,584 matched pairs, treatment with atorva-
statin vs simvastatin was associated with a reduced risk of cardio-
vascular-related hospitalization, higher adherence, and less use of 
other lipid-lowering drugs. The increase in statin costs associated 
with atorvastatin vs simvastatin therapy was almost completely 
offset by reductions in medical service and indirect costs. 
CONCLUSION: In this study, treatment with atorvastatin compared 
with simvastatin was associated with a reduced risk of cardiovas-
cular events, reduced indirect costs, and a minimal difference in 
total costs to employers.
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rienced a lower risk of fatal and nonfatal cardiovascular 
and cerebrovascular events compared with those who 
were prescribed simvastatin and other statins.16 An edito-
rial published in the December 2008 issue of Mayo Clinic 
Proceedings concluded that atorvastatin may be the better 
choice for prevention of cardiovascular disease but that it 
is unclear whether these benefits are considered fully cost-
effective.17
 The aim of the current study was to compare clinical out-
comes and economic outcomes from the employer perspec-
tive between patients in whom atorvastatin or simvastatin 
therapy was initiated. Given that indirect costs to employ-
ers are a substantial component of cardiovascular-related 
disease costs, the current study focused on a privately in-
sured population of US employees in whom indirect costs 
to employers (ie, costs from missed work due to disability 
and medically related absenteeism) could be measured in 
addition to direct medical and pharmacy costs.
PATIENTS AND METHODS
Data were obtained from Ingenix Employer Solutions, a 
privately insured claims database covering approximately 
8 million beneficiaries (including employees, spouses, and 
dependents) from 23 large employers under various insur-
ers, from January 1, 1998, through December 31, 2006. 
Together, these employers have operations throughout the 
United States in a broad array of industries and job clas-
sifications. The data contain deidentified information on 
patient demographics (eg, age, sex), health plan eligibil-
ity, and medical and pharmacy claims. Medical service use 
is recorded with a date of service, associated diagnoses, 
procedures, and paid reimbursed amounts. Paid amounts 
for patient co -payments are recorded. Pharmacy claims are 
associated with National Drug Codes and contain dates of 
prescription fills, days of supply, strengths, quantities, and 
reimbursed amounts. The 23 employers also provide data 
on wages, disability-related work loss, and disability pay-
ments to employees. The current study included only em-
ployed members younger than 65 years to avoid third-party 
payments under Medicare coverage.
 To identify patients in whom statin therapy was newly 
prescribed, we initially included patients with at least 1 
prescription for atorvastatin or simvastatin preceded by at 
least 1 year free of lipid-lowering therapy with any statin 
or with ezetimibe. The index date was defined as the date 
of the first prescription fill for atorvastatin or simvastatin 
(excluding single-pill combinations with ezetimibe). Study 
patients were further required to be active, full-time em-
ployees aged 18 to 64 years on the index date and to be 
continuously enrolled in their health plan for 1 year before 
the index date (baseline period). For the primary analyses, 
selected patients were required to be continuously eligible 
in their health plans for 2 years after the index date to en-
sure equal lengths of follow-up for parallel comparisons of 
health care resource use and cost outcomes. For a sensitiv-
ity analysis, patients were selected using the less restric-
tive criteria of at least 30 days of continuous enrollment 
in their health plan after the index date. Although patients 
in this secondary cohort were required to have 30 days of 
continuous enrollment, all subsequent available continuous 
enrollment was included for analysis.
Study MeaSureS
Patient characteristics were assessed during the 1-year 
baseline period, including demographics (eg, age, sex), 
average wage, initial dose of index drug, selected comor-
bidities (including diabetes mellitus, obesity, hypertension, 
and chronic kidney disease, identified using the Interna-
tional Classification of Diseases, Ninth Revision, Clinical 
Modification codes associated with inpatient or outpatient 
medical services), outpatient cardiovascular-related diag-
noses, inpatient cardiovascular events, medical service use 
(outpatient, inpatient, and emergency department visits), 
medication use, work loss, indirect costs, and all-cause and 
cardiovascular-related prescription and medical service 
costs.
 In the primary analyses with 2 years of continuous 
postindex enrollment available for all patients, the primary 
study outcomes were the rate of inpatient cardiovascular 
events and total costs to employers. Cardiovascular-related 
events were defined through inpatient diagnoses and pro-
cedures, indicating ischemic heart disease, myocardial in-
farction, peripheral vascular disease, aortic aneurysm, an-
gioplasty, coronary artery bypass graft, transient ischemic 
attack, cerebrovascular disease, and congestive heart failure. 
A similar grouping of cardiovascular events has been studied 
in prior analyses of atorvastatin and simvastatin on the ba-
sis of different sources of administrative claims data.14 The 
total cost outcomes examined in the current study include 
all-cause medical costs (services and prescription drugs) in 
addition to indirect costs incurred through work loss and dis-
ability payments and thus represent total costs from an em-
ployer perspective. To provide a complete characterization 
of outcomes for the study cohorts, rates of medical service 
use (outpatient, inpatient, and emergency department visits), 
medication use, work loss hours, and all-cause and cardio-
vascular-related prescription costs were also studied.  
 Initial doses of the index drug were classified as high, 
medium, or low. For atorvastatin, low dose was defined as 
10 mg/d or less, medium dose as 11 through 20 mg/d, and 
high dose as more than 20 mg/d; for simvastatin, low dose 
was defined as 20 mg/d or less, medium dose as 21 through 
40 mg/d, and high dose as more than 40 mg/d.14 Patients 
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were considered adherent with the index prescription if 
their medication possession ratio was 80% or greater; non-
adherence was defined as a medication possession ratio of 
less than or equal to 20%. Work loss was defined as days 
of disability (total time covered by disability claims plus 
an employer-specific period preceding short-term disabil-
ity) and as days of medically related absenteeism identified 
from medical service claims. Indirect costs were identi-
fied from employer payments associated with disability 
claims and from the days of medically related absenteeism 
multiplied by daily wage.18,19 Medical service costs were 
identified as reimbursements from the insurer or managed 
care plan to health care professionals and inflated to year 
2006 dollars. Prescription drug costs were identified as 
reimbursed amounts for pharmacy claims inflated to year 
2006 dollars. Inflation used the medical component of the 
Consumer Price Index. Because simvastatin is currently 
available as a generic medication, paid amounts for sim-
vastatin and atorvastatin were imputed using the average 
reimbursed amounts in 2007 by dose and days of supply.
StatiStical analySeS
Baseline characteristics and outcomes were compared for 
the unmatched atorvastatin cohort vs the simvastatin co-
hort using Wilcoxon rank sum tests for continuous vari-
ables and χ2 tests for categorical variables. Statistical sig-
nificance was defined as P<.05.
 To adjust for imbalance in baseline characteristics be-
tween the atorvastatin and simvastatin cohorts with 2 years 
of continuous postindex enrollment, patients in the ator-
vastatin cohort were matched 1-to-1 to simvastatin users 
for (1) initial drug dose (low, medium, high), (2) baseline 
inpatient cardiovascular events, (3) average wage within 
±$5500, and (4) a propensity score within ±0.05. All 4 cri-
teria were required to be satisfied for each match. Propen-
sity scores were generated from a logistic regression model 
predicting membership in the atorvastatin vs simvastatin 
cohort using a model developed by entering all studied 
baseline characteristics into a stepwise selection algorithm. 
To assess match quality, baseline characteristics were com-
pared between the matched atorvastatin and simvastatin 
patients using Wilcoxon signed rank tests for continuous 
variables and the McNemar test for dichotomous variables. 
Outcomes were similarly compared between the matched 
atorvastatin vs simvastatin cohorts.
 As a sensitivity analysis, time to the first cardiovascular-
related hospitalization, the primary clinical outcome, was 
studied using a multivariate Cox proportional hazards model 
based on the patient sample with at least 30 days of continu-
ous postindex enrollment. The time to first event outcome 
was defined as the time from the index date to the first car-
diovascular-related hospitalization, with patients who had a 
gap in health plan enrollment of more than 30 days treated 
as censored. Thus, these analyses used all available follow-
up during which a patient was continuously enrolled after 
the index date. All baseline characteristics were entered as 
potential predictors into a stepwise selection procedure to 
develop the final multivariate Cox model.
RESULTS
Before matching, sample selection identified 37,661 em-
ployees in whom atorvastatin was prescribed and 13,810 
patients in whom simvastatin was prescribed. Atorvastatin-
treated patients were slightly younger on average and more 
likely to be female, earned a higher average wage, had low-
er co-payments for their index drug, and were less likely 
to be using other medications. Fewer atorvastatin vs sim-
vastatin-treated patients had prior diagnoses of diabetes or 
hypertension or prior outpatient or inpatient cardiovascular 
diagnoses. Atorvastatin vs simvastatin-treated patients had 
lower baseline direct medical costs but higher baseline in-
direct costs and overall lower total costs.
 After matching atorvastatin-treated patients 1-to-1 to 
simvastatin-treated patients on the basis of the propensity 
score, presence of inpatient cardiovascular events, initial 
dose (high, medium, or low), and average wage, 13,584 
matched pairs with 2 years of continuous postindex enroll-
ment were obtained. The matched sample included more 
than 98% (13,584/13,810) of the patients in the smaller 
simvastatin cohort. Baseline characteristics were well bal-
anced between the matched cohorts, although statistically 
significant differences remained, with atorvastatin patients 
having slightly higher preindex all-cause and cardiovas-
cular-related pharmacy costs compared with simvastatin 
patients (by $11 and $6, respectively) and a lower rate of 
prior myocardial infarction (0.60% vs 0.85%) (Table 1). 
The average baseline characteristics of the matched cohorts 
better represent the average baseline characteristics of the 
smaller simvastatin cohort before matching than those of 
the atorvastatin cohort before matching. Simvastatin and 
atorvastatin drug costs were imputed according to the dose 
and days of supply using 2007 pharmacy claims costs ob-
served after generic availability of simvastatin. For exam-
ple, the average reimbursed amounts for a 30-day (90-day) 
supply of generic simvastatin were $12.60 ($65.26) for 10 
mg, $19.88 ($112.48) for 20 mg, $19.07 ($110.98) for 40 
mg, and $18.65 ($108.28) for 80 mg.
 During the 2-year outcome period (Table 2), atorvasta-
tin vs simvastatin patients experienced significantly low-
er rates of total inpatient cardiovascular events (7.5% vs 
8.2%; P=.02). Treatment with atorvastatin vs simvastatin 
was also associated with fewer days of medically related 
absenteeism (12.2 vs 12.5; P=.02) and fewer total work 
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TABLE 1. Baseline Characteristics of Employees Prescribed Atorvastatin and Simvastatin Before and After Matching
  Before matching After matching
    Atorvastatin Simvastatin Atorvastatin Simvastatin
   Baseline characteristics  (n=37,661)  (n=13,810)  (n=13,584)  (n=13,584)
Age, mean ± SD (y) 49.9±7.7 50.6±7.4a 50.6±7.4 50.6±7.4
Female, No. (%)  10,387 (27.6)  3637 (26.3)a 3625 (26.7) 3595 (26.5)
Average annual wage, mean ± SD (2006 US$) 67,620±49,126 61,146±32,747a 60,530±28,354 60,526±28,351
Employees with comorbidities, No. (%)    
 Diabetes mellitus    8704 (23.1)   3403 (24.6)a 3343 (24.6) 3343 (24.6)
 Obesity  2292 (6.1)  826 (6.0) 785 (5.8) 814 (6.0)
 Hypertension 20,867 (55.4)   7972 (57.7)a 7872 (58.0) 7829 (57.6)
 Chronic kidney disease    807 (2.1) 313 (2.3) 323 (2.4) 310 (2.3)
Initial dose of index drug,b No. (%)    
 Low 24,750 (65.7) 9037 (65.4) 8882 (65.4) 8882 (65.4)
 Medium 10,099 (26.8) 4295 (31.1) 4232 (31.2) 4232 (31.2)
 High  2812 (7.5)  478 (3.5) 470 (3.5) 470 (3.5)
Co-pay for index drug, mean ± SD (US$) 17.6±13.2 22.5±15.5a 20.2±13.8 21.7±13.8a
No. of prescriptions, mean ± SDc 1.4±1.9 1.4±1.9 1.4±1.9 1.4±1.9 
Other medication use, No. (%)     
 Antihypertensives 14,956 (39.7)   6119 (44.3)a     6109 (45.0)   6002 (44.2)
 Antidiabetics    6430 (17.1)   2620 (19.0)a     2552 (18.8)   2570 (18.9)
 Thrombolytics     2 (0)   0 (0)    0 (0)    0 (0)
 Antiplatelets  2548 (6.8) 1297 (9.4)a 1243 (9.2) 1247 (9.2)
 Antiarrhythmia drugs    437 (1.2)  181 (1.3)   187 (1.4)   179 (1.3)
 Lipid-lowering (nonstatin) drugs    6989 (18.6)   2840 (20.6)a     2829 (20.8)   2784 (20.5)
Outpatient cardiovascular diagnoses/procedures, No. (%)  3552 (9.4)   1658 (12.0)a     1573 (11.6)   1603 (11.8)
 Ischemic heart disease  2563 (6.8) 1257 (9.1)a  1192 (8.8) 1215 (8.9)
 Myocardial infarction      69 (0.2)     41 (0.3)d        35 (0.3)     37 (0.3)
 Peripheral vascular disease    350 (0.9)  153 (1.1)   149 (1.1)   148 (1.1)
   Aortic aneurysm      82 (0.2)    28 (0.2)     27 (0.2)     27 (0.2)
   Angioplasty    130 (0.4)     69 (0.5)d        71 (0.5)    67 (0.5)
  Coronary artery bypass grafting     2 (0)   3 (0)    2 (0)   3 (0)
   Transient ischemic attack    220 (0.6)   102 (0.7)d        95 (0.7)    98 (0.7)
   Cerebrovascular disease    541 (1.4)  216 (1.6)   215 (1.6)  205 (1.5)
   Congestive heart failure    290 (0.8)   136 (1.0)d    116 (0.9)  128 (0.9)
Inpatient cardiovascular events, No. (%)  1931 (5.1) 1129 (8.2)a 1068 (7.9) 1068 (7.9)
 Ischemic heart disease  1516 (4.0)   913 (6.6)a    863 (6.4)   861 (6.3)
  Myocardial infarction    160 (0.4)   126 (0.9)a        81 (0.6)    116 (0.9)d
   Peripheral vascular disease      90 (0.2)     66 (0.5)a        53 (0.4)    62 (0.5)
  Aortic aneurysm      25 (0.1)    13 (0.1)     14 (0.1)    13 (0.1)
   Angioplasty    797 (2.1)   499 (3.6)a    443 (3.3)  473 (3.5)
   Coronary artery bypass grafting    260 (0.7)   203 (1.5)a    174 (1.3)  184 (1.4)
   Transient ischemic attack    115 (0.3)    57 (0.4)     61 (0.5)    53 (0.4)
   Cerebrovascular disease    286 (0.8)   135 (1.0)d    148 (1.1)  130 (1.0)
   Congestive heart failure    186 (0.5)   131 (1.0)a    101 (0.7)  124 (0.9)
Inpatient cardiovascular event in past 3 mo, No. (%)   1553 (4.1)   955 (6.9)a    890 (6.6)  901 (6.6)
Medical service use, mean ± SD (d)    
 Inpatient    0.6±3.5    0.8±4.2a      0.7±3.6    0.8±3.5
 Emergency department    0.3±0.8    0.3±0.8    0.3±0.7    0.3±0.8
 Outpatient    8.3±10.3    7.9±9.8a      7.8±9.1    7.9±9.8
Work loss, mean ± SD (d)    
 Disability    3.7±25.8    3.9±26.7    4.0±26.9    3.9±26.7
 Medically related absenteeism    5.2±7.6    5.1±7.8a      4.9±6.9    5.1±7.6
 Total     8.8±26.7    8.9±27.6a      8.9±27.5    8.9±27.5
All-cause direct costs, mean ± SD (2006 US$)    
 Pharmacy    783±1875   732±1747a    743±1546   731±1739e
 Medical service  4292±15,633 5249±21,431d 5095±19,666 5109±21,211
 Total  5076±16,033 5981±21,680 5837±19,860 5841±21,464
Cardiovascular-related direct costs, mean ± SD (2006 US$)    
   Pharmacy    121±311   122±296d    128±293   122±297a
   Medical service  1744±10,513 2904±19,278a 2612±14,107 2783±19,171
 Total cardiovascular-related  1865±10,537 3026±19,289a 2740±14,128 2905±19,182
All-cause indirect costs, mean ± SD (2006 US$)  
 Disability   470±3344   507±3678   497±3418   508±3697
 Medically related absenteeism 1301±2365 1147±1948a 1082±1608 1135±1919
 Total indirect  1771±4085 1654±4138a 1579±3764 1643±4142
Total costs (2006 US$) 7063±19,376 7969±26,233e 7726±23,926 7810±26,064
a P<.001. Before matching, Wilcoxon rank sum tests were used for continuous characteristics and χ2 tests were used for categorical characteristics; after 
matching, Wilcoxon signed rank tests were used for continuous characteristics.
b For atorvastatin, low dose was defined as 10 mg or less, medium as more than 10 mg and 20 mg or less, and high as more than 20 mg. For simvastatin, 
low dose was defined as 20 mg or less, medium as more than 20 mg and 40 mg or less, and high as more than 40 mg.
c Number of unique prescriptions filled within 30 days preceding the index date.
d P<.05. 
e P<.01.
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TABLE 2. Comparison of Outcomes Between Matched Cohorts of Employees Prescribed Atorvastatin vs Simvastatin
  Atorvastatin Simvastatin Differencea 
 Outcome  (n=13,584)  (n=13,584) (atorvastatin vs simvastatin) P valueb
Inpatient cardiovascular events, No. (%)  1014 (7.5) 1120 (8.2) 0.91 .02
 Ischemic heart disease  813 (6.0)  895 (6.6) 0.91 .04
 Myocardial infarction   41 (0.3)    70 (0.5) 0.58 .01
   Peripheral vascular disease   58 (0.4)    60 (0.4) 0.98 .85
   Aortic aneurysm   13 (0.1)    19 (0.1) 0.71 .29
   Angioplasty  230 (1.7)   256 (1.9) 0.90 .24
Coronary artery bypass grafting  112 (0.8)  103 (0.8) 1.08 .54
   Transient ischemic attack    62 (0.5)     64 (0.5) 0.98 .86
   Cerebrovascular disease  147 (1.1)  159 (1.2) 0.92 .49
  Congestive heart failure  126 (0.9)  133 (1.0) 0.95 .66
No. of cardiovascular events per 100 employees, mean ± SD 12.7±63.2 13.5±52.3 –0.82 .07
Medication use, No. (%)    
   Adherentc  4937 (36.3)  4494 (33.1) 1.10 <.001
   Nonadherentc  3094 (11.4)  3367 (12.4) 0.92 <.001
Use of other lipid-lowering drugsd  2758 (20.3)  3378 (24.9) 0.82 <.001
   Atorvastatin 13,584 (100.0)  1738 (12.8) 7.82 <.001
   Simvastatin  707 (5.2) 13,584 (100.0) 0.05 <.001
   Other statins 1198 (8.8)  1838 (13.5) 0.65 <.001
  Niacin  553 (4.1)  661 (4.9) 0.84 .002
  Fibrates  916 (6.7)  846 (6.2) 1.08 .09
   Bile acid sequesterants  166 (1.2)  172 (1.3) 0.96 .74
Total No. of index drug prescriptions, mean ± SD 9.6±6.6 9.1±6.5 0.47 <.001
Medical service use, mean ± SD (d)    
   Inpatient 1.2±7.6 1.2±5.0 0.03 .17
   Emergency department 0.7±1.6 0.7±1.7 −0.01 .77
   Outpatient 20.0±19.9 20.4±19.8 −0.41 .06
Work loss, mean ± SD (d)    
   Disability 10.7±60.8 10.6±60.2 0.18 .95
   Medically related absenteeism 12.2±16.1 12.5±15.7 −0.30 .02
   Total  23.0±62.3 23.1±61.5 −0.12 .04
All-cause direct costs, mean ± SD (2006 US$)    
   Pharmacy  2239±2333 1803±2213 436 <.001
   Index drug 946±636 489±389 457 <.001
   Other 1293±2158 1315±2134 −22 .01
   Medical service    9131±24,194    9403±28,610 −272 .52
   Total  11,370±24,734 11,207±29,057 164 <.001
Cardiovascular-related direct costs, mean ± SD (2006 US$)    
   Pharmacy  1196±808 763±603 433 <.001
   Index drug 946±636 489±389 457 <.001
  Other 250±401 275±419 −25 <.001
   Medical service     2889±12,152    3115±13,504 −226 .02
   Total     4085±12,280    3878±13,605 207 <.001
All-cause indirect costs, mean ± SD (2006 US$)    
   Disability   680±3958   697±4148 −17 .71
   Medically related absenteeism 2692±3688 2798±3869 −105 .03
   Total  3372±5382 3495±5644 −123 .01
Total costs, mean ± SD (2006 US$) 14,742±27,482 14,701±31,704 41 .003
Total costs, excluding study drug, mean ± SD (2006 US$) 13,796±27,458 14,213±31,693 −416 .19
Total costs, 9% rebate, mean ± SD (2006 US$) 14,656±27,479 14,701±31,704 −44 .03
a The relative risk was calculated for proportions; the difference was calculated for continuous variables.
b The Wilcoxon signed rank test was used for comparing continuous variables; the McNemar test was used to compare dichotomous variables.
c Adherence was defined as a medical possession ratio greater than or equal to 80%. Nonadherence was defined as a medical possession ratio less than or 
equal to 20%.
d Includes lipid-lowering drugs other than the index statin.
loss days (23.0 vs 23.1; P=.04), higher rates of medication 
adherence (36.3% vs 33.1%; P<.001), and lower rates of 
nonadherence (11.4% vs 12.4%; P<.001), as well as lower 
concomitant use of other lipid-lowering medication (20.3% 
vs 24.9%; P<.001). As expected, pharmacy costs derived 
from index drug costs remained higher for atorvastatin be-
cause of the generic simvastatin ($946 vs $489; P<.001), 
but atorvastatin patients had slightly lower nonindex drug 
costs for all other drugs ($1293 vs $1315; P=.01) and for 
other cardiovascular-related drugs ($250 vs $275; P<.001) 
(Table 2). Treatment with atorvastatin vs simvastatin was 
also associated with lower cardiovascular-related medical 
service costs ($2889 vs $3115; P=.02), lower medically 
related absenteeism costs ($2692 vs $2798; P=.03), and 
Lipid-Lowering Therapy ouTcomes in empLoyees
Mayo Clin Proc.    •    December 2009;84(12):1065-1072    •    doi:10.4065/mcp.2009.0298    •    www.mayoclinicproceedings.com1070
For personal use. Mass reproduce only with permission from Mayo Clinic Proceedings.
lower total indirect costs ($3372 vs $3495; P=.01). In to-
tal, taking into account the direct costs of medical services 
and prescription drugs and indirect costs to employers due 
to disability and medically related absenteeism, treatment 
with atorvastatin was associated with a $41 (0.30%) high-
er total cost to the employer compared with simvastatin 
($14,742 vs $14,701; P=.003) during the 2-year follow-up 
period (Figure and Table 2).
 Agreements between the employer and the insurer or 
the pharmacy benefits management company can involve 
manufacturer rebates that reduce drug acquisition costs. 
Because these rebates are not included in the data source 
used for the current study, cost comparisons for the matched 
atorvastatin and simvastatin cohorts were recalculated us-
ing representative rebate amounts paid by manufacturers 
of brand-name but not generic agents. Although the rebate 
rate fluctuates on the basis of the specific contract between 
employers and health care professionals, 9% functions as 
a simplistic and conservative estimate that should encom-
pass most health care plans. After applying a 9% rebate 
to the atorvastatin pharmacy cost in the 2-year sample, 
atorvastatin therapy was cost saving by $44 compared with 
simvastatin therapy ($14,656 vs $14,701) (Table 2).
Multivariate cox ProPortional HazardS Model
The study sample included 59,370 active full-time employ-
ees aged 18 to 64 years in whom atorvastatin was initiated 
and 23,325 in whom simvastatin was initiated, with con-
tinuous health plan enrollment for at least 30 days after the 
index date. In the multivariate Cox proportional hazards 
model obtained via stepwise selection, treatment with ator-
vastatin vs simvastatin was associated with a statistically 
significant 11% reduction in the hazard of cardiovascular-
related hospitalization (hazard ratio, 0.89; 95% confidence 
interval, 0.85-0.95; P=.001). Baseline characteristics that 
were significantly associated with an increased hazard of 
inpatient cardiovascular events included older age, male 
sex, lower wage, baseline diabetes, hypertension, chronic 
kidney disease, use of medium (vs high) dose of the index 
statin, use of antihypertensives, use of antiplatelets, use of 
antidiabetics, use of antiarrhythmics, prior inpatient diag-
noses of peripheral vascular disease, and prior cardiovas-
cular events in the past 3 months.
DISCUSSION
In this observational study of an employed population, 
treatment with atorvastatin vs simvastatin was associated 
with a reduced risk of cardiovascular-related hospitaliza-
tion and a minimal difference in total costs to employers. 
This study suggests that, despite a substantial difference in 
the drug acquisition costs between the brand-name ator-
vastatin and the generic simvastatin, atorvastatin treatment 
leads to only minimally higher costs to employers and 
may result in cost savings if drug rebates are included. The 
higher drug acquisition costs for atorvastatin were largely 
offset by reduced costs for medical services and reduced 
indirect costs.
 These findings are important to payers and self-insured 
employers attempting to reduce overall costs by reducing a 
pharmacy budget. Although it can be relatively straightfor-
ward to implement programs designed to increase the use 
of generic statins over more expensive brand-name agents 
and to measure the impact of such programs on pharmacy 
costs, our findings suggest that, in the case of atorva statin 
and simvastatin, cost savings predicted by this type of 
silo budget analysis would not materialize in bottom-line 
costs to employers. Another example of how the pharmacy 
budget may be a misleading proxy for overall health care 
costs is a recent analysis concluding that, for patients who 
had either no or minimal drug coverage, the increase in 
pharmacy spending as a result of enrollment in Medicare 
part D was essentially offset by reductions in other medical 
spending.20 Appropriate pharmaceutical treatment of other 
chronic diseases has also been associated with increased 
productivity and reduced indirect costs to employers.21
 The clinical explanation for reduced resource use in 
atorvastatin-treated patients could not be determined in the 
current study. Better adherence to atorvastatin may contrib-
ute to this explanation.14,22,23 In addition, evidence suggests 
that the 2 agents may differ in their nonlipid effects, such as 
the reduction in inflammation.24 The association between 
FIGURE. Total 2-year costs and cost components for matched pa-
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inflammatory markers and cardiovascular events has re-
ceived increased attention after the publication of JUPITER 
(Justification for the Use of Statins in Primary Prevention: 
An Intervention Trial Evaluating Rosuvastatin), in which ro-
suvastatin therapy was shown to benefit patients with normal 
low-density lipoprotein cholesterol levels (<130 mg/dL) but 
elevated levels of the inflammatory marker C-reactive pro-
tein.25 Multiple studies have shown that atorvastatin signifi-
cantly reduces high-sensitivity C-reactive protein levels,26-29 
whereas a study of simvastatin found reductions of smaller 
magnitude,30 and a comparative study found that atorvastatin 
was associated with greater high-sensitivity C-reactive pro-
tein reductions compared with simvastatin.31
 Previous observational studies of statin therapy in the 
general (not necessarily employed) population for both 
primary prevention and all new statin users13-15 have con-
sistently shown a relative risk reduction associated with 
atorvastatin therapy of 10% to 13%, which is roughly in 
line with the 9% relative risk reduction in our analysis. 
Taken together, the consistency across studies suggests a 
robust association between initiation with atorvastatin and 
reduced cardiovascular risk that is not sensitive to differ-
ences across administrative claims databases, statistical 
methods (Cox regression vs propensity score matching), 
employment status, or small variations in sample selection 
and study design. It would be informative to assess whether 
the risk reduction and corresponding cost offsets could be 
replicated in a prospective, randomized cardiovascular out-
comes trial with comparable doses.
 Although our findings are based on a mixed primary and 
secondary prevention population, they are consistent with 
the health economic analyses of the IDEAL (Incremental 
Decrease in Endpoints Through Aggressive Lipid Lower-
ing) trial, which investigated the cost-effectiveness of high-
dose atorvastatin therapy relative to regular-dose simvastatin 
therapy among patients with established coronary heart dis-
ease in several European populations; this study also found 
substantial indirect cost savings associated with atorvastatin 
vs simvastatin.19 Although statin acquisition costs for atorva-
statin therapy are significantly more expensive compared 
with generic simvastatin therapy, this difference was partially 
offset by reduced medical and indirect costs. However, ator-
vastatin therapy was only moderately cost-effective relative 
to simvastatin in the IDEAL trial, possibly because the gener-
ic simvastatin daily drug cost, ranging from €0.07 to €0.30 
for simvastatin at 20 mg, or approximately $2.90 to $12.30 
for a 30-day supply, was assumed to be significantly lower 
compared with the amount paid by a typical US employer 
in the current study (using the generic simvastatin pricing 
identified after 2007). Although the time frame for the cur-
rent study extended only 6 months past the initial approval 
of generic simvastatin, generic simvastatin drug prices were 
imputed throughout to better represent the current reimburse-
ment environment for privately insured US employers.
 Our study consists of a large number of patients, but ad-
ministrative claims data have limitations. As in all nonran-
domized, observational studies, it is necessary to adjust for 
patient characteristics that may be associated with treatment 
choice and outcomes.32 We attempted to adjust for all poten-
tially important confounding variables that were in the data 
source, including prior cardiovascular events, but it is pos-
sible that unmeasured confounding variables were present.
 The measurement of indirect cost outcomes in the cur-
rent study was limited and may underestimate the total in-
direct costs to employers. It was not possible to compare 
losses in productivity or presenteeism for statin-treated 
patients or the costs to employers of lost productivity of 
coworkers or of hiring replacement staff for patients with 
absenteeism due to cardiovascular events, early retirement, 
or early mortality.33,34 Also, because disability payments 
were not associated with particular diagnoses or dates of 
absence from work, classification of disability payments 
as cardiovascular related was not possible. The average an-
nual wage observed in this patient cohort (approximately 
$60,000) is somewhat higher than the median annual wage 
of US employees, which may limit the generalizability of 
the findings, particularly because wage data are used to cal-
culate indirect costs. Because the matching-adjusted anal-
yses primarily adjusted the atorvastatin cohort to match 
the baseline characteristics of the simvastatin cohort, the 
treatment effects of atorvastatin vs simvastatin pertain to 
patients typically treated with simvastatin during the study 
period. As with any analysis of administrative claims, data 
may contain errors in coding or underrepresentation of cer-
tain comorbidities. For example, the rates of recorded obe-
sity diagnoses in this study were much lower than would be 
expected for the general US population. However, because 
even inaccurate diagnoses can be associated with cardio-
vascular risk, ensuring balance between study groups for 
all relevant recorded comorbidities can provide helpful 
adjustment for confounding variables. Moreover, claims 
data may not contain all clinical assessments of interest. 
For example, in the current study, laboratory values, such 
as serum lipid levels, were not available and could not be 
directly adjusted between the atorvastatin and simvastatin 
cohorts. The 2-year follow-up period may not have been 
long enough to capture all outcomes associated with the 
initial statin prescription. Long-term differences in health 
care resource use, work loss, and costs could persist as 
lifelong consequences of cardiovascular events experienced 
during the 2-year study period. An additional limitation of 
the data source was that mortality, which could differ be-
tween treatment cohorts given the differences in cardiovas-
cular event rates, could not be assessed. Finally, the primary 
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outcomes were inpatient cardiovascular event rates and total 
costs to employers. Multiple other outcomes were analyzed 
to support the interpretation of the primary outcomes and 
to provide hypotheses for potential future research, but no 
statistical adjustment was made for multiple comparisons.
CONCLUSION
This study found that active employees in whom lipid-low-
ering therapy with atorvastatin, rather than simvastatin, was 
initiated experienced a lower risk of cardiovascular-related 
hospitalizations, consistent with previous observational 
studies. Initiation of statin therapy with the less-expen-
sive generic simvastatin did not result in any meaningful 
total cost savings to employers. The higher drug acquisi-
tion costs for atorvastatin were largely offset by reduced 
cardiovascular-related medical service costs and reduced 
indirect costs. The net total cost difference of $41 indicates 
that atorvastatin, relative to simvastatin, is a cost-effective 
intervention in this patient population and, after assuming 
typical rebates, may even be cost saving.
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